Paragon BioTeck, Inc. Appoints New U.S. Medical Advisor
Dr. Paul S. Koch to advise company clinical programs, regulatory strategy and current and future research programs
Tigard, OR (PRWEB) March 06, 2013
Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, has announced the addition of prominent ophthalmologist Paul S. Koch, M.D. as its U.S. medical advisor. Dr. Koch will play a key role in advising Paragon on its clinical programs, regulatory strategy and current and future research programs.
“Dr. Koch has been the catalyst to some of the most important advances in this area of medicine, and we look forward to his valuable insight and participation,” said Patrick Witham, president and CEO of Paragon BioTeck, Inc.
The founder and medical director of Koch Eye Associates in Warwick, R.I., Dr. Koch has been named one of the Top 100 Ophthalmologists and one of the Top 15 Cataract Surgeons in North America by Ophthalmology Times. He has been cited in each issue of the “Best Doctors in America.” He has won many awards, including the Mericos H. Whittier Foundation´s Lifetime Achievement Award, the American Academy of Ophthalmology´s Honor Award, the David Kelman Foundation´s Golden Hands Award, Cataract and Refractive Surgery Today´s Nordan Award, the Irish-American Ophthalmology Society´s Top-Gun Phaco Award and the International Film Festival of the American Society of Cataract & Refractive Surgery Award, which he has received four times. He was also in the inaugural group of inductees into the Bishop Hendricken High School Hall of Fame.
“I am thrilled to be part of an organization with such an interesting portfolio of properties,” Dr. Koch said. “I expect Paragon BioTeck to continue to make significant contributions to eye care through the development of these properties and spinoff innovations.”
About Paragon BioTeck, Inc.
Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight. For more information on the company and its work, visit http://www.paragonbioteck.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10496871.htm